

John Fanikos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4415469/publications.pdf>

Version: 2024-02-01

95
papers

2,296
citations

257101

24
h-index

223531

46
g-index

97
all docs

97
docs citations

97
times ranked

3367
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. <i>New England Journal of Medicine</i> , 2019, 380, 1606-1617.	13.9	266
2	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2060-2072.	1.2	230
3	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 83-97.	0.6	133
4	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016, 129, 1198-1204.	0.6	121
5	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 15-31.	1.0	108
6	Hospital Costs of Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2013, 126, 127-132.	0.6	103
7	Anticoagulation-associated Adverse Drug Events. <i>American Journal of Medicine</i> , 2011, 124, 1136-1142.	0.6	92
8	“Inactive” ingredients in oral medications. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	68
9	Major Bleeding Complications in a Specialized Anticoagulation Service. <i>American Journal of Cardiology</i> , 2005, 96, 595-598.	0.7	65
10	Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1290-1299.	1.2	65
11	Medication errors associated with anticoagulant therapy in the hospital. <i>American Journal of Cardiology</i> , 2004, 94, 532-535.	0.7	62
12	Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. <i>American Journal of Cardiology</i> , 2004, 93, 247-250.	0.7	61
13	Long-term complications of medical patients with hospital-acquired venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 102, 688-693.	1.8	59
14	Adherence to Pharmacological Thromboprophylaxis Orders in Hospitalized Patients. <i>American Journal of Medicine</i> , 2010, 123, 536-541.	0.6	55
15	Thrombosis in Suspected Heparin-induced Thrombocytopenia Occurs More Often with High Antibody Levels. <i>American Journal of Medicine</i> , 2012, 125, 44-49.	0.6	55
16	Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. <i>American Journal of Medicine</i> , 2012, 125, 258-264.	0.6	45
17	Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1130-1135.	1.8	44
18	Impact of Smart Infusion Technology on Administration of Anticoagulants (Unfractionated Heparin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	42

#	ARTICLE	IF	CITATIONS
19	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
20	Adverse Drug Events in Hospitalized Cardiac Patients. <i>American Journal of Cardiology</i> , 2007, 100, 1465-1469.	0.7	38
21	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 1015-1023.	0.6	38
22	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <i>Drugs</i> , 2015, 75, 1627-1644.	4.9	37
23	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. <i>Thrombosis and Haemostasis</i> , 2020, 120, 027-035.	1.8	35
24	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. <i>Clinical Cardiology</i> , 2017, 40, 46-52.	0.7	25
25	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
26	Kratom from Head to Toe—Case Reviews of Adverse Events and Toxicities. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 141-168.	0.6	24
27	Reversal agents for use with direct and indirect anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s27-s48.	0.5	20
28	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987603.	0.7	20
29	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	0.6	18
30	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. <i>American Journal of Emergency Medicine</i> , 2016, 34, 46-51.	0.7	16
31	Patient-Reported Outcomes from A National, Prospective, Observational Study of Emergency Department Acute Pain Management With an Intranasal Nonsteroidal Anti-inflammatory Drug, Opioids, or Both. <i>Academic Emergency Medicine</i> , 2016, 23, 331-341.	0.8	15
32	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
33	The frequency of inappropriate nonformulary medication alert overrides in the inpatient setting. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 924-933.	2.2	14
34	Efficacy and safety of novel anticoagulants compared with established agents. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 175-195.	1.1	13
35	Medication Use Evaluation: Pharmacist Rubric for Performance Improvement. <i>Pharmacotherapy</i> , 2014, 34, 5S-13S.	1.2	13
36	Venous Thromboembolism Prophylaxis for Medical Service—Mostly Cancer—Patients at Hospital Discharge. <i>American Journal of Medicine</i> , 2011, 124, 1143-1150.	0.6	12

#	ARTICLE	IF	CITATIONS
37	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. American Journal of Medicine, 2016, 129, S89-S96.	0.6	12
38	Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in U.S. hospitals. American Journal of Health-System Pharmacy, 2007, 64, 2037-2043.	0.5	10
39	ASHP Guidelines on Medication-Use Evaluation. American Journal of Health-System Pharmacy, 2021, 78, 168-175.	0.5	10
40	The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. American Journal of Emergency Medicine, 2020, 38, 1163-1170.	0.7	9
41	Contemporary NSTEMI management: the role of the hospitalist. Hospital Practice (1995), 2020, 48, 1-11.	0.5	9
42	Biosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners. Current Emergency and Hospital Medicine Reports, 2013, 1, 226-235.	0.6	8
43	The Pharmacist Discharge Care (PHARM-DC) study: A multicenter RCT of pharmacist-directed transitional care to reduce post-hospitalization utilization. Contemporary Clinical Trials, 2021, 106, 106419.	0.8	8
44	Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia. Pharmacotherapy, 2013, 33, 1191-1198.	1.2	7
45	Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. American Journal of Hematology, 2015, 90, E143-5.	2.0	7
46	Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. American Journal of Medicine, 2017, 130, 1137-1143.	0.6	7
47	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. TH Open, 2018, 02, e33-e38.	0.7	7
48	Opioid-Free Recovery After Hernia Repair with HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting: A Randomized, Open-Label Study. Pain and Therapy, 2021, 10, 1295-1308.	1.5	6
49	Cost-effectiveness of andexanet Alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US. Journal of Medical Economics, 2022, 25, 309-320.	1.0	6
50	Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 2019, 132, 16-24.	0.6	5
51	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. Journal of Atrial Fibrillation, 2016, 9, 1481.	0.5	5
52	An assessment of currently available i.v. push medication delivery systems. American Journal of Health-System Pharmacy, 2017, 74, e230-e235.	0.5	4
53	Unfractionated Heparin and Low-Molecular-Weight Heparin. , 2018, , 31-57.		4
54	Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. American Journal of Health-System Pharmacy, 2021, 78, 1568-1575.	0.5	4

#	ARTICLE	IF	CITATIONS
55	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.	1.8	4
56	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. <i>Blood</i> , 2011, 118, 2062-2062.	0.6	4
57	Risk Factors for the Assessment of Patients with Pulmonary Embolism. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 871-880.	2.3	3
58	Aligning pharmacy and health-system objectives to eliminate central-line-associated bacteremias. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 2189-2197.	0.5	3
59	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 54-61.	0.6	3
60	Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety. <i>Journal of General Internal Medicine</i> , 2018, 33, 2005-2007.	1.3	3
61	Regulatory and Clinical Perspective on Biosimilars: a Comparison of the US and European Experiences. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 111-117.	0.6	3
62	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 331-335.	1.0	3
63	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	1.0	3
64	Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2017, 17, 132-135.	0.2	3
65	Regulatory Impact on Thrombosis Treatment, Prevention, and Anticoagulant Use. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1115-1135.	0.9	2
66	Best Practices for Medication Utilization Evaluations in Postsurgical Pain Management. <i>Current Emergency and Hospital Medicine Reports</i> , 2017, 5, 33-40.	0.6	2
67	Drug formulary decision-making: Ethnographic study of 3 pharmacy and therapeutics committees. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 537-542.	0.5	2
68	Management of a parenteral opioid shortage using ASHP guidelines. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 426-435.	0.5	2
69	Cleveland Clinic International IV Robotics Summit. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 800-805.	0.5	2
70	The Reply. <i>American Journal of Medicine</i> , 2017, 130, e365-e366.	0.6	1
71	Why Does the Food and Drug Administration Need to Ban Kratom?. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 169-174.	0.6	1
72	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.2	1

#	ARTICLE	IF	CITATIONS
73	Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability. <i>Journal of Clinical Lipidology</i> , 2020, 14, 315-321.e4.	0.6	1
74	Implementation of Pharmacy Executive Quality and Safety Walkrounds at a Tertiary Academic Medical Center. <i>Hospital Pharmacy</i> , 2022, 57, 211-216.	0.4	1
75	Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis. <i>Blood Advances</i> , 2021, 5, 5283-5289.	2.5	1
76	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.2	1
77	Visual compatibility of perphenazine with various antimicrobials during simulated Y-site injection. <i>American Journal of Health-System Pharmacy</i> , 1987, 44, 574-575.	0.5	0
78	Stability of bacitracin solution frozen in glass vials or plastic syringes. <i>American Journal of Health-System Pharmacy</i> , 1987, 44, 1125-1127.	0.5	0
79	Visual Compatibility of Famotidine with Commonly used Critical-care Medications During Simulated Y-site Injection. <i>American Journal of Health-System Pharmacy</i> , 1988, 45, 1556-1557.	0.5	0
80	Total Parenteral Nutrition Preparation for a Known Latex-Allergic Patient. <i>Hospital Pharmacy</i> , 2001, 36, 746-749.	0.4	0
81	Submassive Pulmonary Embolism: Risk Evaluation and Role of Fibrinolysis. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 236-246.	0.6	0
82	Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. <i>Journal of Medical Economics</i> , 2013, 16, 1190-1192.	1.0	0
83	Regulatory, legislative, and policy updates with anticoagulant use. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 273-287.	1.0	0
84	Assessment of the Impact of Nursing Interruptions on Pharmacist Workflow and Efficiency. <i>Hospital Pharmacy</i> , 2016, 51, 49-53.	0.4	0
85	Invited Commentary: Initial Experience with Direct Oral Anticoagulants in the Perioperative Setting. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 88-92.	0.6	0
86	Prescribing Naloxone: Managing and Preventing Opioid-Related Overdoses. <i>Current Emergency and Hospital Medicine Reports</i> , 2017, 5, 11-15.	0.6	0
87	Intravenous and Oral Hyperammonemia Management. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 182-193.	0.6	0
88	Use of P2Y12 inhibitors among Medicaid beneficiaries between 2008 and 2018. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 539-541.	1.0	0
89	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.	0.6	0
90	87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up. <i>Open Forum Infectious Diseases</i> , 2019, 6, S5-S5.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 158-160.	1.0	0
92	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 22-29.	1.0	0
93	Non-Sterile to Sterile Compounding: An Unconventional Response During the COVID-19 Pandemic. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110178.	0.5	0
94	Characteristics of the ideal clinical pharmacy residency candidate: A survey of residency program directors and preceptors in Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 66-71.	1.2	0
95	Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review. <i>International Journal of Pharmaceutical Compounding</i> , 2020, 24, 346-351.	0.0	0